Navigation Links
Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
Date:8/16/2011

st and most advanced is a NADH oxidase inhibitor program that includes lead candidate ME-143 (formerly NV-143). The second is a mitochondrial inhibitor program that includes lead candidate ME-344 (formerly NV-344). The Company expects to initiate a Phase I clinical trial of intravenous ME-143 by September 2011 and submit an Investigational New Drug application for ME-344 by the first quarter of 2012. For more information, please visit www.marshalledwardsinc.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
2. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
3. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
4. Marshall Edwards Announces Private Placement
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Receives Positive Response From NASDAQ
7. Marshall Edwards to Host Annual Meeting of Stockholders
8. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
9. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
10. Medical Device Consultants, Inc. Welcomes Brian Edwards, Senior Regulatory Staff Consultant
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... DIEGO , July 30, 2014   ... biotech company that designs and develops novel diagnostics ... of cancer, announced today the completion of a ... financing included new investors RusnanoMedInvest (RMI) and Arcus ... and Pfizer Venture Investments, as well as undisclosed ...
(Date:7/30/2014)... , 30. Juli 2014 ... ein führender Anbieter im Bereich Atemtherapie- und ... des Landgerichts München in Deutschland anfechten werden. ... bestimmten Masken ein Patent von ResMed verletze. ... in wichtigen Ländern gegen verschiedene Patente von ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today ... Key results include: , Total revenues increased 11 ... growth driven by strong performance across the portfolio, particularly ... ® (denosumab) and XGEVA ® (denosumab). ... by higher revenues and a significant increase in the ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
... SUNNYVALE, Calif., Dec. 28, 2010 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that its president and chief executive officer, ... 29th Annual J.P. Morgan Healthcare Conference in San Francisco on ... A live webcast of the presentation will be ...
... Medical Group Inc. (Nasdaq: WWIN ), ("Winner ... and non-woven fabric made from 100% natural PurCotton® products ... was recently held by Winner Medical and Cotton Incorporated ... in a high footprint shopping mall in Shanghai. ...
Cached Medicine Technology:Accuray Incorporated's CEO to Speak at 29th Annual J.P. Morgan Healthcare Conference 2Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 2Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 3Winner Medical and Cotton Inc. Promote PurCotton(R) Brand and Natural(TM) Trademark in Shanghai 4
(Date:7/30/2014)... 30, 2014 Decene is an ... chain of ten carbon atoms with one double ... of 1-decenes. It can be used as a ... to produce epoxides, amines, oxo alcohols, synthetic lubricants, ... Early buyers will receive 10% customization on this ...
(Date:7/30/2014)... 2014 Naomi Fried, PhD, and ... of Directors of the American Telemedicine Association (ATA). ... which has a mission to promote professional, ethical ... and information technology. , “Both Naomi Fried and ... extraordinary expertise and are well known experts in ...
(Date:7/30/2014)... 2014 (HealthDay News) -- Clues to whether a person is ... test, a new study suggests. Chemical changes to a ... help spur suicidal thoughts and behaviors, the study,s authors explained. ... doctors to a patient,s risk for suicide, they said. ... have been stymied in our prevention efforts because we have ...
(Date:7/30/2014)... 2014 The global digital pathology market was ... expected to grow at a CAGR of 11.8%, to reach ... digital pathology is growing and is expected to continue to ... scanners and image analysis software enable pathologists to be efficient ... In 2013, the North American market was valued at $128.9 ...
(Date:7/30/2014)... This news release is available in French . ... Inserm, led by Claude Gronfier (Inserm Unit 846: Stem ... conducted a study under real conditions on the body ... Concordia. The researchers have shown that a particular kind ... biological rhythms are correctly synchronised despite the absence of ...
Breaking Medicine News(10 mins):Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Dimly lit working environments: Correcting your body clock is possible! 2Health News:Dimly lit working environments: Correcting your body clock is possible! 3Health News:Dimly lit working environments: Correcting your body clock is possible! 4
... impairment that strikes in the early stages of prion diseases such ... ,The findings suggest there may be a way to cure ... before it has time to kill off large numbers of brain ... lives of 158 people in Britain, and seven more are known ...
... recently discovered genes from an ancient wheat variety have led ... ,In a recent set of papers published in the ... as Nax1 and Nax2. The genes work by excluding salt ... the other from the leaves. The discovery of the two ...
... is a neighborhood which renders immense potential to walk around, ... revealed in a survey conducted by// Ethan Berke of Dartmouth ... for publication in the March issue of American Journal of ... group of 65-97. Some of the parameters that were analyzed ...
... more slowly in women and older adults, a new study at ... to the skin heal more quickly in women than in men, ... inside the mouth," said Dr. Phillip Marucha, head of periodontics at ... of age, men's mouth wounds heal faster than women's." ...
... practice guidelines for diagnosis and management of venous thromboembolism.// ... clotting in the veins. ,Key elements of ... rules to establish pretest probability of deep vein thrombosis ... and the utility of various diagnostic tools such as ...
... the application filed before the Hon’ble Supreme Court, the ... to ST candidates in the All India Quota seats ... session 2007-08. While disposing of this application for directions ... case Vs Union of India, WP 18/2006, Hon’ble Supreme ...
Cached Medicine News:Health News:Researchers Make Strides in VCJD Detection 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2Health News:Oral Wounds Heal Slower in Women, Older Adults 2Health News:New Guidelines for Diagnosis of Venous Thromboembolism 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Medicine Products: